encephalitis

Yinyao Lin, Mengyan Hu, Haiyan Li, Sanxin Liu, Xuejiao Men, Yilong Shan, Sha Tan, Xuehong Huang, Zhengqi Lu*, Bingjun Zhang*

Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, No 600 Tianhe Road, Guangzhou, Guangdong 510630, China

Yinyao Lin, Mengyan Hu and Haiyan Li contributed equally to this work

*Correspondence: Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, No 600 Tianhe Road, Guangzhou, Guangdong 510630, China. E-mail: gdbingjun@163.com

*Correspondence: Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, No 600 Tianhe Road, Guangzhou, Guangdong 510630, China. E-mail: lzq1828@outlook.com

Abstract

Objective: This study aims to find whether there are differences of clinical and laboratory features between anti-NMDAR encephalitis patients with and without brain atrophy. We also compare brain atrophy scale in anti-NMDAR positive patients with and without teratomas.

Methods: Brain atrophy scales of 82 patients with anti-NMDAR encephalitis were measured with the median temporal lobe atrophy (MTA) scale and the global cortical atrophy (GCA) scale. They were divided into two groups by brain atrophy status. In addition, 48 female patients with
anti-NMDAR encephalitis were divided into two groups with or without teratomas. Percentages of patients with brain atrophy were compared between these two groups.

**Results:** 33 (40.2%) patients had brain atrophy. The GCA (+) group had higher percentage of patients with status epilepticus (p<0.001) than GCA (-) group and the MTA (+) group had higher percentage of patients with memory deficits (p < 0.001) than MTA (-) group. Higher percentages of severe infections were found in GCA(+) and MTA (+) groups than those in GCA(-) and MTA (-) groups (p=0.01 and p = 0.002, respectively). The percentage of patients needing ventilatory support was higher in MTA (+) group than that in MTA (-) group (p=0.015). The modified Rankin Scale (mRS) scores of GCA(+) and MTA (+) groups were significantly higher when compared with GCA(-) and MTA (-) groups both at day one (p<0.001 and p=0.001, respectively) and at discharge (p<0.001 and p = 0.02, respectively). Patients in GCA (+) group had higher median length of hospital stay than those in GCA (-) group (p<0.001). The median onset-to-MR time of GCA(+) group was higher than that of GCA(-) group (p=0.034). Percentage of patients with limited response to treatment was higher in GCA (+) group than that in GCA(-) group (p<0.001). The median 25 hydroxyvitamin D3 level was lower in the GCA (+) group than that in GCA(-) group (p=0.001). Anti-NMDAR positive female patients with ovarian teratomas had higher percentage of
GCA(+) than those without ovarian teratomas (P=0.006).

**Conclusions:** Brain atrophy are not uncommon in patients with anti-NMDAR encephalitis. MTA and GCA may be associated with severity and prognosis of anti-NMDAR encephalitis.

**Key words:** Brain atrophy; anti-NMDAR encephalitis; GCA; MTA

1. **Introduction**

Anti-N-methyl- D -aspartate receptor (anti-NMDAR) encephalitis is a form of inflammatory encephalopathies in association with antibodies (immunoglobulin G) against the GluN1 subunit of the NMDAR. It predominantly affects young women with or without ovarian teratomas [1-3].

A variety of magnetic resonance imaging (MRI) findings have been reported in patients with anti-NMDAR encephalitis [2, 4-6]. However, few studies focus on the brain atrophy in anti-N-methyl-D-aspartate receptor encephalitis. Iizuka et al found that cerebellar atrophy was irreversible and associated with poor outcome in patients with anti-N-methyl-D-aspartate receptor encephalitis [7]. However, This study based on only 15 patients. Further studies are needed to confirm the clinical association between brain atrophy and anti-N-methyl-D-aspartate receptor encephalitis.
This study aims to find whether there are differences of clinical and laboratory features between anti-NMDAR encephalitis patients with and without brain atrophy.

2. Methods

2.1. Study population

Our database comprised 82 patients with anti-NMDAR encephalitis who were admitted from March 2014 to December 2018 in the department of neurology of the Third Affiliated Hospital of Sun Yat-sen University. Anti-NMDAR encephalitis was diagnosed in the presence of a core syndrome of limbic encephalitis (psychiatric symptoms, seizures, conscious disturbance and memory deficits) and detection of IgG antibodies against NMDAR [8]. And it is important to carefully exclude relevant differential diagnoses. Gender, age, modified Rankin Scale (mRS) and clinical manifestations were recorded. All patients underwent routine abdominal and pelvic ultrasound. And a pelvic computed tomography (CT) scan or magnetic resonance imaging (MRI) scan was performed when an ovarian teratoma was suspected. Treatments included first-line immunotherapy, second-line immunotherapy and tumour removal. First-line immunotherapy included the use of steroids, intravenous immunoglobulins or plasma exchange alone or combined. Second-line immunotherapy included rituximab, azathioprine or cyclophosphamide treatment alone or combined. The initial treatment
was recorded as a failure if no sustained improvement occurred within 1 month of initiation of immunotherapy or tumour removal, and if the mRS score remained at 4 or higher.

2.2. Detection of autoantibodies

After obtaining informed consent, cerebrospinal fluid (CSF) was collected from patients prior to treatment with methylprednisolone and other immunotherapies. The CSF sample was used for routine analysis and autoantibodies. Antibodies against NMDAR were tested by indirect immunofluorescence assay using commercial sampling kits (EUROIMMUN Medizinische Labordiagnostika, Lübeck, Germany).

2.3. Magnetic resonance imaging (MRI) and visual rating scales

Brain MRI scans were performed at 3.0 Tesla (Discovery MR750, GE Healthcare, Milwaukee, WI, USA). The slice thickness of the axial scans was 5 mm. Conventional MRI protocols were applied to all patients: T2-weighted (4392-5658/88.8-106 ms, TR/TE), T1-fluid-attenuated inversion recovery (FLAIR) (1782.6-1925.4/19.2-24.6 ms, TR/TE) and T2 FLAIR (8,400-8800/139.4-151.4 ms, TR/TE) for brain MRI.

Brain atrophy was measured with the median temporal lobe atrophy (MTA) scale based on T1-weighted images and the global cortical atrophy (GCA) scale based on the T2-flair images as detailed before [9, 10]. The MTA scale was developed in 1992 by Scheltens et al., evaluating the choroid fissure, the temporal horn of the lateral ventricles
and the height of the hippocampus on a scale of 0 – 4 where a higher score means more atrophy in the region (table1) [9]. We evaluated severity of GCA according to Pasquier and co-workers on a 4-point rating scale (0 = no atrophy; 1=mild GCA, sulcal opening peripherally; 2=moderate GCA, widening along the length of the sulci; 3=severe GCA, gyral thinning [10]. A neurologist and a neuroradiologist independently read all MRIs, blinded to clinical data.

2.4. Statistics analyses

All statistical analyses were conducted by using the SPSS 13.0 package for Windows (SPSS Inc, Chicago, IL, USA). Continuous data were presented as the mean ± standard deviation or median (range). Continuous data were compared by Student's t-test or the Mann Whitney U test. Nominal variables were analyzed using the chi-square test or Fisher's exact test.

3. Results

3.1. Baseline demographics and clinical characteristics among patients with anti-N-methyl- D-aspartate receptor encephalitis

Baseline demographics and clinical characteristics of patients with anti-N-methyl-D-aspartate receptor encephalitis were summarized in Table 2. The patients enrolled included 34 males (41.5%) and 48 females (58.5%) with ages ranging from 3 to 64 years. Among them, 58 patients (70.7%) were older than 18 years, 18 patients (22.0%) had a tumor, 52
patients (63.4%) had epileptic seizures, 64 patients (78.0%) had psychiatric symptoms, 43 patients (52.4%) had conscious disturbance, 35 patients (42.7%) had memory deficits and 33 patients (40.2%) had brain atrophy. The median MRS score was 4 (range, 1-5) at day one and 1 (range, 0-5) at discharge. The median length of hospital stay was 27.5 (range, 5-111). The median onset-to-MRI time was 42 (range, 2-1464). 80 patients (97.6%) received first-line treatment, 38 (46.3%) received combined first-line and second-line treatment, and 17 (20.7%) received tumour removal treatment.

3.2. Clinical correlation between anti-NMDAR encephalitis patients with and without brain atrophy

As shown in Table 3, patients with anti-NMDAR encephalitis were divided into two groups based on MTA and GCA scale. The GCA (+) group had higher percentage of female patients than that in GCA(-) group (p=0.029). No significant difference was found for median age and percentage of patients older than 18 years. As for the clinical presentation at onset, the GCA (+) group had higher percentage of patients with status epilepticus (p<0.001) than GCA (-) group and the MTA (+) group had higher percentage of patients with memory deficits (p < 0.001) than MTA (-) group. No significant difference was found for psychiatric symptoms and conscious disturbance. Higher percentages of severe infections were found in GCA(+) and MTA (+) groups than those in GCA(-) and MTA (-)
groups (p=0.01 and p = 0.002, respectively). The percentage of patients needing ventilatory support was higher in MTA (+) group than that in MTA (-) group (p=0.015). The modified Rankin Scale (mRS) scores of GCA(+) and MTA (+) groups were significantly higher when compared with GCA(-) and MTA (-) groups both at day one (p<0.001 and p=0.001, respectively) and at discharge (p<0.001 and p=0.02, respectively). Patients in GCA (+) group had higher median length of hospital stay than those in GCA (-) group (p<0.001). The median onset-to-MR time of GCA(+) group was higher than that of GCA(-) group (p=0.034). Percentage of patients with limited response to treatment was higher in GCA (+) group than that in GCA(-) group (p<0.001). As for laboratory test results, the median 25 hydroxyvitamin D3 level was lower in the GCA (+) group than that in GCA(-) group (p=0.001). There was no difference in percentage of patients receiving first line combined with second line treatment, CSF abnormalities, median antibody titers, median vitamin B1 level, median vitamin B2 level, median vitamin B6 level, median vitamin B12 level and mean folic acid level between patients with and without brain atrophy.

3.3. Comparison of brain atrophy in anti-NMDAR positive female patients with and without teratomas

Among the anti-NMDAR positive 48 female patients, 17 patients had ovarian teratoma and 31 patients were non-tumor associated. And we
found that anti-NMDAR positive female patients with ovarian teratomas had higher percentage of GCA (+) and higher median mRS score both at day one and at discharge than those without ovarian teratomas (P=0.006, p=0.037 and P=0.0033, respectively). The mean folic acid level of anti-NMDAR positive female patients with teratomas was lower than that of patients without teratomas (p=0.024). There was no difference in mean age, percentage of patients with MTA (+), percentage of status epilepticus, percentage of severe infections, median vitamin B1 level, median vitamin B2 level, median vitamin B6 level, median vitamin B12 level and median 25 hydroxyvitamin D3 level between the two groups.

4. Discussion

This study focused on the characteristics of anti-NMDAR encephalitis patients with brain atrophy. Previous studies demonstrated grey matter atrophy in patients with multiple sclerosis and neuromyelitis optical [11]. In multiple sclerosis, deep grey matter has been recognised as a crucial component of the disease and has been associated with disability [12]. In neuromyelitis optical, hippocampal volume is the main MRI predictor of cognition [13]. However, little is known about brain atrophy in anti-NMDAR encephalitis. In this study, more than one third had brain atrophy on plain MRI films measured with MTA scale and GCA scale in total 82 patients with anti-NMDAR encephalitis. This result demonstrated that brain atrophy were not uncommon in patients with anti-NMDAR
encephalitis. Medial temporal lobe atrophy as assessed by MTA was observed in 14.1% of patients on at least 1 side and this finding is consistent with that in a previous study [14].

We found the GCA (+) group had higher percentage of female patients. This result may due to that all patients with teratoma were female in our study and we found that anti-NMDAR positive female patients with ovarian teratomas were more likely to have GCA than those without teratomas.

For clinical symptoms, we found that the MTA (+) group had higher percentage of patients with memory deficits than MTA (-) group. MTA-scale was usually used to assess degree of hippocampus atrophy on plain MRI films. A previous study demonstrated that the degree of MTA was significantly correlated with scores on memory tests, which was consistent with our finding [9].

We found that the median onset-to-MR time of the GCA (+) group was 60 which was higher than that of the GCA (-) group. A previous study demonstrated that brain atrophy in anti-NMDAR encephalitis started 1 to 2 month after symptom onset, which was consistent with our finding [7].

We also found that the modified Rankin Scale (mRS) scores of MTA (+) groups were significantly higher when compared with MTA (-) groups. A previous literature indicated that left hippocampal volume could predict disease severity [15] which was consistent with that in our
study. Also higher mRS scores were observed in patients with GCA. Patients with GCA were more likely to have limited response to treatment, need ventilatory support and had higher median length of hospital stay. The findings suggested that MTA and GCA may be associated with severity and prognosis of anti-NMDAR encephalitis. Lizuka et al reported several patients with anti-NMDAR encephalitis developed diffuse cerebral atrophy who had severe dyskinesias and they slowly recovered 3 to 4 years after symptom onset. Also, their brain atrophy were reversible [16]. So further studies are needed to confirm the association between long-term MRI changes and clinical outcome of patients with anti-NMDAR encephalitis.

The mechanisms of brain atrophy in anti-NMDAR encephalitis remain largely unknown. In this study we found that patients with brain atrophy had higher percentages of status epilepticus, severe infection and lower 25 hydroxyvitamin D3 level. According to previous studies, these factors may be associated with brain atrophy [17-19].

Previous studies indicated that an ovarian tumor could be found in approximately 26.9% to 44.2% of female patients with anti-NMDAR encephalitis [5, 20, 21] which was consistent with our finding (35.4%). We found that anti-NMDAR positive patients with ovarian teratomas were more likely to have GCA than patients without ovarian teratomas. We also found that patients with teratomas had higher mRS scores which
was consistent with the result in a previous literature [21]. Patients with a teratoma develop more robust immune responses than those without a tumour [22] and tend to present more severe neurological conditions [21]. In addition, we found that patients with teratomas had lower level of folic acid. A previous study conducted by Snowdon et al showed that low serum folate was strongly associated with atrophy of the cerebral cortex [23], though the mechanism remains to be determined.

5. Limitations and conclusions

There are some limitations in this study: (a) because we only enrolled patients with anti-NMDAR encephalitis, our conclusions may not be applied to patients with other types of autoimmune encephalitis; (b) bias is inevitable in retrospective studies; (c) we did not perform follow up of MR changes in this study.

In summary, this study confirmed that brain atrophy was not uncommon in patients with anti-NMDAR encephalitis. MTA and GCA may be associated with severity and prognosis of anti-NMDAR encephalitis. Also we found that anti-NMDAR positive patients with ovarian teratomas were more likely to have GCA than patients without ovarian teratomas. The exact mechanism of brain atrophy in anti-NMDAR encephalitis need further study.

Ethics approval and consent to participate

This research was approved by the ethics committee of the Third
Affiliated Hospital of Sun Yat-sen University.

Consent for publication

All participants involved in this study provided written informed consent.

Data availability statements

The datasets analysed during the current study available from the corresponding author on reasonable request.

Competing interests

None.

Funding

This study was supported by the Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program (QHJH201907) and Guangdong Basic and Applied Basic Research Foundation (2020A1515010056).

Authors' contributions

Yinyao Lin: design of the work; Mengyan Hu and Haiyan Li: the acquisition, analysis; Sanxin Liu and Xuejiao Men: interpretation of data; Yilong Shan and Sha Tan: have drafted the work; Xuehong Huang and Zhengqi Lu: substantively revised it.

Acknowledgments

Not applicable

Authors' information
None additional authors' information were showed.

References

1. Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med 2018;378:840-851.
2. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61(1):25-36.
3. Tanguturi YC, Cundiff AW, Fuchs C. Anti-N-Methyl d-Aspartate Receptor Encephalitis and Electroconvulsive Therapy: Literature Review and Future Directions. Child Adolesc Psychiatr Clin N Am 2019;28:79-89.
4. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
5. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157-65.
6. Titulaer MJ, Höfberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75:411-28.
7. Iizuka T, Kaneko J, Tominaga N, et al. Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis. JAMA Neurol. 2016;73:706-13.
8. Leyboldt F. Autoimmune encephalitiden [Autoimmune encephalitis]. Fortschr Neurol Psychiatr 2013;81:523-37.
9. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-72.
10. Pasquier F, Leys D, Weerts JG et al. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268-72.
11. Duan Y, Liu Y, Liang P, et al. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study. Eur J Radiol 2012;81:e110-4.
12. Polacek H, Kantorova E, Hnilicova P, et al. Increased glutamate and deep brain atrophy can predict the severity of multiple sclerosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2019;163:45-53.
13. Liu Y, Fu Y, Schoonheim MM, et al. Structural MRI substrates of cognitive impairment in neuromyelitis optica. Neurology. 2015 Oct 27;85(17):1491-9.
14. Zhang T, Duan Y, Ye J, et al. Brain MRI Characteristics of Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations With 2-Year Clinical Outcome. AJNR Am J Neuroradiol 2018;39(5):824-829.
15. Finke C, Kopp UA, Pajkert A, et al. Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Biol Psychiatry 2016;79:727-734.
16. Iizuka T, Yoshii S, Kan S, et al. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol 2010;257:1686-91.
17. Mendes A, Sampaio L. Brain magnetic resonance in status epilepticus: A focused review. Seizure. 2016;38:63-7.
18. Orhun G, Tüzün E, Bilgiç B, et al. Brain Volume Changes in Patients with Acute Brain Dysfunction Due to Sepsis. Neurocrit Care 2020;32(2):459-468.
19. Annweiler C, Annweiler T, Montero-Odasso M, et al. Vitamin D and brain volumetric changes: Systematic review and meta-analysis. Maturitas 2014;78:30-9.
20. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-8.
21. Dai Y, Zhang J, Ren H, et al. Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma. Am J Obstet Gynecol. 2019;221:485.e1-485.e10.
22. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.
23. Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr 2000;71:993-8.
Table 1 Scoring according to the Scheltens MTA scale

| MTA score | Width of the choroid fissure | Width of the temporal horn | Height of Hippocampal formation |
|-----------|------------------------------|----------------------------|--------------------------------|
| 0         | N                            | N                          | N                              |
| 1         | †                            | N                          | N                              |
| 2         | † †                          | †                          | ↓                              |
| 3         | † † †                        | † †                        | ↓ ↓                            |
| 4         | † † † †                      | † † †                      | ↓ ↓ ↓                           |

Reproduced from Scheltens et al., 1992 (9).
MTA, medial temporal lobe atrophy.
Table 2 Baseline characteristics of anti-NMDAR encephalitis patients

| Characteristics                                      | Anti-NMDAR encephalitis |
|------------------------------------------------------|-------------------------|
|                                                      | N=82                    |
| F/M, n                                               | 48/34                   |
| Age (y, median, range)                               | 22.5 (3, 64)            |
| Patients with age ≥ 18 years, n (%)                  | 58 (70.7)               |
| Tumour comorbidity (n, %)                            | 18 (22.0)               |
| ovarian teratoma                                     | 17 (20.7)               |
| Colon carcinoma                                      | 1 (1.2)                 |
| Clinical presentation at onset, n (%)                |                         |
| Epileptic seizures                                   | 52 (63.4)               |
| Behavioral and psychiatric disturbances              | 64 (78.0)               |
| Conscious disturbance                                | 43 (52.4)               |
| memory deficits                                      | 35 (42.7)               |
| Patients with encephalatrophy, n (%)                 | 33 (40.2)               |
| Patients with GCA positive on MRI                    | 30 (36.6)               |
| Patients with MTA (one side/both sides) positive on MRI | 12 (14.6)           |
| mRS score at day one (median, range)                 | 4 (1, 5)                |
| mRS score at discharge (median, range)               | 1 (0, 5)                |
| Length of hospital stay (median, range)              | 27.5 (5, 111)           |
| Onset-to-MRI time (median, range)                    | 42 (2, 1464)            |
| Treatment (n, %)                                     |                         |
| First line treatment                                 | 80 (97.6)               |
| First line combined with second line treatment       | 38 (46.3)               |
| Tumour removal                                       | 17 (20.7)               |
| CSF abnormalities, n (%)                             | 55 (67.1)               |
| Antibody titers (median, range)                      | 1:32 (1:1, 1:320)       |

NMDAR, N-methyl-d-aspartate receptor; F, female; M, male; y, year; GCA, global cortical atrophy; MTA, temporal lobe atrophy; mRS, modified Rankin score; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging
Table 3 Comparison of clinical features in anti-NMDAR encephalitis patients with and without encephalatrophy

|                          | GCA (+) | GCA (-) | P     | MTA (+) | MTA (-) | P     |
|--------------------------|---------|---------|-------|---------|---------|-------|
|                          | N=28    | N=54    |       | N=12    | N=70    |       |
| F/M, n                   | 21/7    | 27/27   | 0.029 | 6/6     | 42/28   | 0.516 |
| Age (y, median, range)   | 26 (12, 64) | 21.5 (3, 50) | 0.057 | 22 (8, 64) | 23 (3, 58) | 0.749 |
| Patients with age ≥18 years, n (%) | 23 (82.1) | 35 (64.8) | 0.102 | 9 (75.0) | 49 (70.0) | 0.993 |
| Clinical presentation at onset, n (%) |     |         |       |         |         |       |
| Epileptic seizures       | 21 (75.0) | 31 (57.4) | 0.117 | 10 (83.3) | 42 (60.0) | 0.220 |
| Status epilepticus       | 13 (46.4) | 9 (16.7) | 0.004 | 6 (50.0) | 16 (22.9) | 0.108 |
| Psychiatric symptoms     | 23 (82.1) | 41 (75.9) | 0.519 | 8 (66.7) | 56 (80.0) | 0.513 |
| Conscious disturbance    | 17 (60.7) | 26 (48.1) | 0.280 | 7 (58.3) | 36 (51.4) | 1.000 |
| Memory deficit           | 15 (53.6) | 20 (37.0) | 0.151 | 11 (91.7) | 24 (34.3) | <0.001 |
| Severe infection, n (%)  | 12 (42.9) | 9 (16.7) | 0.01  | 8 (66.7) | 13 (18.6) | 0.002 |
| Ventilatory support, n (%)| 7 (25.0) | 5 (9.3) | 0.113 | 5 (41.7) | 7 (10.0) | 0.015 |
| mRS score at day one (median, range) | 4.5 (3, 5) | 3 (1, 5) | <0.001 | 5 (3, 5) | 4 (1, 5) | 0.001 |
| mRS score at discharge (median, range) | 4 (2, 5) | 1 (0, 5) | <0.001 | 3 (2, 5) | 2 (0, 5) | 0.02  |
| Length of hospital stay (median, range) | 37.5 (10, 111) | 25 (5, 54) | <0.001 | 37.5 (11, 60) | 27.5 (5, 111) | 0.178 |
| Onset-to-MR time (median, range) | 60 (30, 375) | 38.5 (2, 1464) | 0.034 | 70 (20, 189) | 40.5 (2, 1464) | 0.051 |
| Limited response to treatment, n (%) | 15 (53.6) | 6 (11.1) | <0.001 | 3 (25.0) | 18 (25.7) | 1.000 |
| First line combined with second line treatment, n (%) | 16 (57.1) | 22 (40.7) | 0.158 | 3 (25.0) | 35 (50.0) | 0.109 |
| CSF abnormalities, n (%) | 19 (67.9) | 36 (66.7) | 0.913 | 11 (91.7) | 44 (62.9) | 0.103 |
| Antibody titers (median, range) | 1:66 (1:1, 1:320) | 1:32 (1:1, 1:100) | 0.063 | 1:32 (1:3, 1:320) | 1:32 (1:1, 1:320) | 0.979 |
| Vitamin B1 (nmol/L, median, range) | 51.3 (44.4, 123.6) | 69.5 (40.0, 143.9) | 0.473 | 77.5 (41.5, 143.9) | 65.8 (40.0, 141.4) | 0.476 |
| Vitamin B12 (μg/L, median, range) | 198.6 (184.2, 379.5) | 231.7 (178.1, 398.9) | 0.972 | 195.2 (184.2, 263.2) | 229.5 (178.1, 398.9) | 0.283 |
| Vitamin B6 (μmol/L, median, range) | 21.2 (10.3, 45.9) | 20.9 (7.5, 77.6) | 0.596 | 17.6 (10.3, 24.0) | 22.1 (7.5, 77.5) | 0.095 |
| Vitamin B12 (pg/ml, median, range) | 225.2 (170.5, 487.4) | 256.7 (184.1, 420.7) | 0.127 | 216.1 (184.2, 311.3) | 256.3 (170.5, 487.4) | 0.1 |
| Folic acid (nmol/L, mean ± SD) | 10.0± 4.4 | 11.8±3.2 | 0.34 | 13.1±5.5 | 10.4±5.6 | 0.271 |
| 25 hydroxyvitamin D3 (nmol/L, median, range) | 39.5 (22, 90) | 64.1 (25, 120) | 0.001 | 63.5 (25, 90) | 55.7 (22, 120) | 0.404 |

NMDAR, N-methyl-d-aspartate receptor; GCA, global cortical atrophy; MTA, temporal lobe atrophy; F, female; M, male; y, year; mRS, modified Rankin Scale; MR, magnetic resonance; CSF, cerebrospinal fluid; SD, Standard Deviation.

A, N=22; a, N=43; B, N=12; b, N=53; C, N=23; c, N=43; D, N=9; d, N=57; E, N=17; e, N=39; F, N=6; f, N=50; G, N=22; g, N=44; H, N=8; h, N=58; I, N=24; i, N=44; J, N=10; j, N=58; K, N=11; k, N=9; L, N=3; l, N=17; M, N=22; m, N=39; O, N=9; o, N=52.
## Table 4 Comparison of encephalatrophy in NMDAR-Ab positive female patients with and without teratomas

|                                      | NMDAR-Ab (+) patients with teratomas | NMDAR-Ab (+) patients without teratomas | P       |
|--------------------------------------|--------------------------------------|-----------------------------------------|---------|
| Mean age (y, mean ± SD)              | 23.2 ± 5.6                           | 23.0 ± 10.6                             | 0.503   |
| GCA (+), n (%)                       | 12 (70.6)                            | 9 (29.0)                                | 0.006   |
| MTA (+), n (%)                       | 1 (5.9)                              | 5 (16.1)                                | 0.568   |
| Status epilepticus, n (%)            | 8 (47.1)                             | 7 (22.6)                                | 0.272   |
| Severe infection, n (%)              | 9 (52.9)                             | 9 (29.0)                                | 0.102   |
| mRS score at day one (median, range) | 5 (3, 5)                             | 4 (2, 5)                                | 0.037   |
| mRS score at discharge (median, range)| 3 (0, 5)                             | 2 (0, 5)                                | 0.033   |
| Vitamin B1 (mmol/L, median, range)   | 80.2 (47.7, 108.0)                   | 69.4 (40.0, 143.9)                      | 0.796   |
| Vitamin B2 ( μ g/L, median, range)   | 196.4 (178.3, 379.5)                 | 256.3 (179.2, 378.4)                    | 0.172   |
| Vitamin B6 ( μ mol/L, median, range) | 19.9 (12.7, 35.2)                    | 21.6 (10.2, 52.6)                       | 0.926   |
| Vitamin B12 (pg/mL, median, range)   | 292.4 (190.1, 487.4)                 | 251.0 (170.5, 456.3)                    | 0.08    |
| Folic acid (nmol/L, mean ± SD)       | 5.8 ± 1.2                            | 11.8 ± 3.9                              | 0.024   |
| 25 hydroxyvitamin D3 (nmol/L, median, range) | 36 (22, 92) | 57.6 (23, 120) | 0.096   |

NMDAR-Ab, N-methyl-d-aspartate receptor antibody; y, year; SD, Standard Deviation; GCA, global cortical atrophy; MTA, temporal lobe atrophy; mRS, modified Rankin Scale. A, N=9; a, N=27; B, N=7; b, N=21; C, N=9; c, N=26; D, N=10; d, N=27; E, N=3; e, N=11; F, N=10; f, N=23.
Fig. 1. FLAIR MRI (TR 8400, TE 148.4) showing GCA according to Pasquier and co-workers (mild GCA, score 2)

Fig. 2. T1 MRI (TR 1791.4, TE 19.2) showing MTA according to Scheltens and co-workers (score 2).